Mobilizing the
Human Immune System
to Combat Disease
HiFiBiO Therapeutics is an emerging multinational company that seeks to transform patient care.
Home
Mobilizing the
Latest News
May 9, 2022
Lynn Bodarky Joins HiFiBiO Therapeutics as SVP, Global Head of Business Development and Alliance Management
CAMBRIDGE, Mass. – May 9th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Lynn Bodarky as a Senior Vice President to oversee the company’s business development and alliance management activities, reporting directly to HiFiBiO’s President and CEO, Dr. Liang Schweizer. “We are very excited to bring on board an … Continued
Apr 27, 2022
HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, MA – April 27th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today that clinical trial investigator, Alexander I Spira, MD, PhD, FACP, Co-Director of the Virginia Cancer Specialists (VCS) Research Institute and Director of the Thoracic and Phase I Program, will present a Trials in Progress Poster for HFB200301 on Sunday, … Continued
May 9, 2022
Lynn Bodarky Joins HiFiBiO Therapeutics as SVP, Global Head of Business Development and Alliance Management
CAMBRIDGE, Mass. – May 9th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Lynn Bodarky as a Senior Vice President to oversee the company’s business development and alliance management activities, reporting directly to HiFiBiO’s President and CEO, Dr. Liang Schweizer. “We are very excited to bring on board an … Continued
Unprecedented Discovery and Development Engine
Unique
Back
Unique
• Comprehensive DIS™ platform IP: Single Cell (CelliGo™) and AI Data Analytics (Absolution™)
• High quality single cell data collection from cancer and autoimmune diseases
• Discovery of therapeutics based in immune modulation rather than disease types
Innovative
Back
Innovative
• Live single B cell screening (5K cells/second) for unprecedented deep immune repertoire mining
• Single cell analysis and data intelligence for indication and biomarker-driven patient selection
• Single cell immune profiling with machine learning to identify disease relevant novel targets
• Next generation bi-specific antibody platforms
Impactful
Back
Impactful
• High quality antibody drug candidates
• Enhanced patient responses
• Shortened drug discovery and clinical development timelines with reduced resources
• Comprehensive DIS™ platform IP: Single Cell (CelliGo™) and AI Data Analytics (Absolution™)
• High quality single cell data collection from cancer and autoimmune diseases
• Discovery of therapeutics based in immune modulation rather than disease types
• Live single B cell screening (5K cells/second) for unprecedented deep immune repertoire mining
• Single cell analysis and data intelligence for indication and biomarker-driven patient selection
• Single cell immune profiling with machine learning to identify disease relevant novel targets
• Next generation bi-specific antibody platforms
• High quality antibody drug candidates
• Enhanced patient responses
• Shortened drug discovery and clinical development timelines with reduced resources